Pembrolizumab Immune-Related Adverse Event Severity Score

Grade pembrolizumab and other PD-1/PD-L1 inhibitor immune-related adverse events by organ system using CTCAE v5, with NCCN/SITC-aligned management (hold, high-dose steroids, infliximab, hospitalization).

Use the full interactive calculator below, or

Related Calculators

Frequently Asked Questions